Cell injury in human islets induced by non-immune mediated inflammation occur in vitro upon
hyperglycemia in type 2 diabetes mellitus. Infusion of autologous bone marrow mononuclear
cells (BMMNCs) is an emerging therapeutic approach for DM, which showed promising outcomes
with mild side effects. Infusion of BMMNCs and autologous bone marrow mesenchymal stem cells
in combination might exert enhanced repairing effects. We hypothesized that infusion of these
two classes of cells might provide multiple signals for regeneration and improve recovery
from inflammation-induced lesion. The effects might be maximized by intra-arterial pancreatic
infusion.